Neurocysticercosis: Clinical Aspects, Immunopathology, Diagnosis, Treatment and Vaccine Development | OMICS International| Abstract
ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • Epidemiol 2014, Vol 4(3): 156
  • DOI: 10.4172/2161-1165.1000156

Neurocysticercosis: Clinical Aspects, Immunopathology, Diagnosis, Treatment and Vaccine Development

José Ramón Vielma1,3, Haideé Urdaneta-Romero2, Juana Del Carmen Villarreal1, Luis Alberto Paz1, Luis Vicente Gutiérrez1, Marylú Mora3 and Leonor ChacĂ­n- Bonilla4*
1Laboratorio de Análisis Químico (LAQUNESUR), Universidad Nacional Experimental Sur del Lago "Jesús María Semprum" UNESUR, Santa Bárbara de Zulia, estado Zulia, , Venezuela
2Instituto de Inmunología Clínica (IDIC), Facultad de Medicina, Universidad de Los Andes, Mérida, estado Mérida, , Venezuela
3Laboratorio de Neurobiología, Centro de Investigaciones Biomédicas, Instituto Venezolano de Investigaciones Científicas (CIB – IVIC), Maracaibo, estado Zulia, , Venezuela
4Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, Facultad de Medicina, Universidad del Zulia, Maracaibo, estado Zulia, , Venezuela
*Corresponding Author : Leonor ChacĂ­n- Bonilla, Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, Facultad De Medicina, Universidad Del Zulia, Maracaibo, Venezuela, Tel: +58-414-652-4576, Fax: +58-261-759-7247, Email: [email protected]

Received Date: Jan 26, 2014 / Accepted Date: Apr 27, 2014 / Published Date: Apr 30, 2014


Neurocysticercosis (NCC) is defined as human parasitism caused by Taenia solium in its larval stage, when the parasite is located at the central nervous system of the human beings. This disease represents a serious public health problem in developing countries. Neuroimaging studies are usually abnormal, but in most cases, not pathognomonic. Serological diagnosis of NCC is made by means of tests using crude antigens or semipurified fractions of T. solium cysticerci or the use of recombinant antigens that have improved the sensitivity and specificity of the diagnosis. Treatment of NCC is based upon the use of cystocidal drugs, namely: praziquantel and albendazole. Some vaccines to prevent porcine cysticercosis are in advanced stages of investigation, but they are not to be used in humans. Nowadays, the T. solium genome sequence will allow to create a rational design of new healing and preventive drugs. A vaccine for human taeniosis use could be developed in a short term. The aim of this review is to describe the most important clinical aspects of the NCC with emphasis in immunopathology and immune diagnosis.

Keywords: Neurocysticercosis; Taenia solium; Immunopathology; Serological diagnosis; Treatment; Vaccines

Citation: Vielma JR, Urdaneta-Romero H, Villarreal JC, Paz LA, Gutiérrez LV, et al. (2014) Neurocysticercosis: Clinical Aspects, Immunopathology, Diagnosis, Treatment and Vaccine Development. Epidemiol 4:156. Doi: 10.4172/2161-1165.1000156

Copyright: © 2014 Vielma JR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.